{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:28:19Z","timestamp":1781000899515,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s11916-023-01169-4","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T12:04:58Z","timestamp":1694088298000},"page":"673-678","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Post-stroke Headache"],"prefix":"10.1007","volume":"27","author":[{"given":"Monica","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Thaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"1169_CR1","unstructured":"Stroke Facts | cdc.gov. https:\/\/www.cdc.gov\/stroke\/facts.htm. Accessed 23 May 2023."},{"key":"1169_CR2","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/j.1526-4610.2009.01440.x","volume":"49","author":"RW Evans","year":"2009","unstructured":"Evans RW, Mitsias PD. Headache at onset of acute cerebral ischemia. Headache. 2009;49:902\u20138.","journal-title":"Headache"},{"key":"1169_CR3","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Harriott AM, Karakaya F, Ayata C. Headache after ischemic stroke. Neurology. 2020;94:e75\u2013e86. A systematic review of 50 studies examining the prevalence and characteristics of new-onset post-stroke headache.","DOI":"10.1212\/WNL.0000000000008591"},{"key":"1169_CR4","doi-asserted-by":"crossref","unstructured":"Olesen J. Headache classification committee of the international headache society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"1169_CR5","doi-asserted-by":"crossref","unstructured":"Lai J, Harrison RA, Plecash A, Field TS, Lai J, Plecash A, et al. A narrative review of persistent post-stroke headache\u2013a new entry in the international classification of headache disorders, 3rd Edition.\u00a0Headache. 2018;58:1442\u201353.","DOI":"10.1111\/head.13382"},{"key":"1169_CR6","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/j.1532-2149.2012.00123.x","volume":"16","author":"AP Hansen","year":"2012","unstructured":"Hansen AP, Marcussen NS, Klit H, Andersen G, Finnerup NB, Jensen TS. Pain following stroke: a prospective study. Eur J Pain. 2012;16:1128\u201336.","journal-title":"Eur J Pain"},{"key":"1169_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1177\/0333102414545894","volume":"35","author":"AP Hansen","year":"2015","unstructured":"Hansen AP, Marcussen NS, Klit H, Kasch H, Jensen TS, Finnerup NB. Development of persistent headache following stroke: a 3-year follow-up. Cephalalgia. 2015;35:399\u2013409.","journal-title":"Cephalalgia"},{"key":"1169_CR8","doi-asserted-by":"crossref","unstructured":"Carvalho Dias M, Martins T, Bas\u00edlio G, Lucas Neto L, Caeiro L, Ferro JM, et al. Headache at the chronic stage of ischemic stroke.\u00a0Headache. 2020;60:607\u201314.","DOI":"10.1111\/head.13761"},{"key":"1169_CR9","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Lebedeva ER, Ushenin AV, Gurary NM, Gilev DV, Kislyak NV, Olesen J. Persistent headache after first-ever ischemic stroke: clinical characteristics and factors associated with its development. J Headache Pain. 2020;23:1\u201310. A prospective cohort study examining the prevalence, characteristics, and treatment of PPSH.","DOI":"10.1186\/s10194-022-01479-9"},{"key":"1169_CR10","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/j.1468-2982.2008.01550.x","volume":"28","author":"JH Kim","year":"2008","unstructured":"Kim JH, Suh SI, Seol HY, Oh K, Seo WK, Yu SW, et al. Regional grey matter changes in patients with migraine: a voxel-based morphometry study. Cephalalgia. 2008;28:598\u2013604.","journal-title":"Cephalalgia"},{"key":"1169_CR11","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1212\/01.wnl.0000183067.94400.80","volume":"65","author":"T Schmidt-Wilcke","year":"2005","unstructured":"Schmidt-Wilcke T, Leinisch E, Straube A, K\u00e4mpfe N, Draganski B, Diener HC, et al. Gray matter decrease in patients with chronic tension type headache. Neurology. 2005;65:1483\u20136.","journal-title":"Neurology"},{"key":"1169_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/brain\/awv333","volume":"139","author":"CL Seifert","year":"2016","unstructured":"Seifert CL, Sch\u00f6nbach EM, Magon S, Gross E, Zimmer C, F\u00f6rschler A, et al. Headache in acute ischaemic stroke: a lesion mapping study. Brain. 2016;139:217\u201326.","journal-title":"Brain"},{"key":"1169_CR13","doi-asserted-by":"crossref","unstructured":"Oliveira FAA, Sampaio Rocha-Filho PA. Headaches attributed to ischemic stroke and transient ischemic attack. Headache. 2019;59:469\u201376.","DOI":"10.1111\/head.13478"},{"key":"1169_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/FNEUR.2010.00016","author":"SJ Wang","year":"2010","unstructured":"Wang SJ, Chen PK, Fuh JL. Comorbidities of migraine. Front Neurol. 2010. https:\/\/doi.org\/10.3389\/FNEUR.2010.00016.","journal-title":"Front Neurol"},{"key":"1169_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/head.13435","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Rains JC, Pavlovic JM, Fanning KM, Reed ML, Manack Adams A, et al. Sleep disorders among people with migraine: results from the chronic migraine epidemiology and outcomes (CaMEO) Study. Headache. 2019;59:32.","journal-title":"Headache"},{"key":"1169_CR16","doi-asserted-by":"crossref","unstructured":"Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021\u201339.","DOI":"10.1111\/head.14153"},{"key":"1169_CR17","doi-asserted-by":"crossref","unstructured":"Diener HC. The risks or lack thereof of migraine treatments in vascular disease. Headache. 2020;60:649\u201353.","DOI":"10.1111\/head.13749"},{"key":"1169_CR18","doi-asserted-by":"crossref","unstructured":"Leroux E, Rothrock J. Triptans for migraine patients with vascular risks: new insights, new options. Headache. 2019;59:1589\u201396.","DOI":"10.1111\/head.13656"},{"key":"1169_CR19","doi-asserted-by":"crossref","unstructured":"Zebenholzer K, Gall W, Gleiss A, Pavelic AR, W\u00f6ber C. Triptans and vascular comorbidity in persons over fifty: findings from a nationwide insurance database\u2013a cohort study. Headache. 2022;62:604\u201312.","DOI":"10.1111\/head.14304"},{"key":"1169_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-017-0811-5","volume":"18","author":"S Benemei","year":"2017","unstructured":"Benemei S, Cortese F, Labastida-Ram\u00edrez A, Marchese F, Pellesi L, Romoli M, et al. Triptans and CGRP blockade\u2013impact on the cranial vasculature. J Headache Pain. 2017;18:1\u20137.","journal-title":"J Headache Pain"},{"key":"1169_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11916-022-01064-4","volume":"26","author":"J Robblee","year":"2022","unstructured":"Robblee J, Harvey LK. Cardiovascular disease and migraine: are the new treatments safe? Curr Pain Headache Rep. 2022;26:647\u201355.","journal-title":"Curr Pain Headache Rep"},{"key":"1169_CR22","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/ana.25831","volume":"88","author":"IA Mulder","year":"2020","unstructured":"Mulder IA, Li M, de Vries T, et al. Anti-migraine calcitonin gene\u2013related peptide receptor antagonists worsen cerebral ischemic outcome in mice. Ann Neurol. 2020;88:771.","journal-title":"Ann Neurol"},{"key":"1169_CR23","doi-asserted-by":"publisher","first-page":"E2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91:E2211\u201321.","journal-title":"Neurology"},{"key":"1169_CR24","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113\u201322.","journal-title":"N Engl J Med"},{"key":"1169_CR25","doi-asserted-by":"publisher","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Silberstein SD, Yeung PP, Cohen JM, Ning X, Yang R, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine. Neurology. 2020;95:e2487\u201399.","journal-title":"Neurology"},{"key":"1169_CR26","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394:1030\u201340.","journal-title":"Lancet"},{"key":"1169_CR27","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392:2280\u20137.","journal-title":"Lancet"},{"key":"1169_CR28","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026\u201337.","journal-title":"Cephalalgia"},{"key":"1169_CR29","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine. Neurology. 2020;94:e1365\u201377.","journal-title":"Neurology"},{"key":"1169_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40:241\u201354.","journal-title":"Cephalalgia"},{"key":"1169_CR31","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim BK, L\u00e1inez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19:814\u201325.","journal-title":"Lancet Neurol"},{"key":"1169_CR32","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","volume":"322","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322:1887\u201398.","journal-title":"JAMA"},{"key":"1169_CR33","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","volume":"381","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381:2230\u201341.","journal-title":"N Engl J Med"},{"key":"1169_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, et al. Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397:51\u201360.","journal-title":"Lancet"},{"key":"1169_CR35","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385:695\u2013706.","journal-title":"N Engl J Med"},{"key":"1169_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-018-0948-x","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20:1\u201333.","journal-title":"J Headache Pain"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-023-01169-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-023-01169-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-023-01169-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:17:51Z","timestamp":1702340271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-023-01169-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1169"],"URL":"https:\/\/doi.org\/10.1007\/s11916-023-01169-4","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,7]]},"assertion":[{"value":"28 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}